FDA
-
-
-
-
-
-
-
FibroGen completes $220 million sale of China unit to AstraZeneca
-
-
-
-
-
-
-
FibroGen (FGEN) Sells FibroGen China to AstraZeneca (AZN) for $160M
-
-
-
-
-
-
-
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (m
-
-
-
-
-
-
-
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
-
-
-
-
-
-
-
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-1, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
-
-
-
-
-
-
-
What Negative Roxadustat FDA AdCom Vote Means for Fibrogen's (FGEN) Stock?
-
322,898 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

